ATRI vs. OSUR, ANIK, CERS, INO, UTMD, ICUI, SILK, FNA, KIDS, and AORT
Should you be buying Atrion stock or one of its competitors? The main competitors of Atrion include OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Cerus (CERS), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), ICU Medical (ICUI), Silk Road Medical (SILK), Paragon 28 (FNA), OrthoPediatrics (KIDS), and Artivion (AORT). These companies are all part of the "medical" sector.
Atrion (NASDAQ:ATRI) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends.
OraSure Technologies has a net margin of 13.23% compared to Atrion's net margin of 11.46%. OraSure Technologies' return on equity of 14.50% beat Atrion's return on equity.
Atrion has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
66.2% of Atrion shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 22.8% of Atrion shares are held by insiders. Comparatively, 3.4% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
OraSure Technologies received 419 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 69.90% of users gave OraSure Technologies an outperform vote while only 55.60% of users gave Atrion an outperform vote.
OraSure Technologies has higher revenue and earnings than Atrion. OraSure Technologies is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
OraSure Technologies has a consensus price target of $6.38, suggesting a potential upside of 16.12%. Given OraSure Technologies' higher probable upside, analysts clearly believe OraSure Technologies is more favorable than Atrion.
In the previous week, Atrion had 2 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Atrion and 3 mentions for OraSure Technologies. Atrion's average media sentiment score of 0.91 beat OraSure Technologies' score of 0.65 indicating that Atrion is being referred to more favorably in the media.
Summary
OraSure Technologies beats Atrion on 10 of the 17 factors compared between the two stocks.
Get Atrion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
